stockportfolio.pro
CRL vs MDGL: Which Stock Is the Better Buy?
Charles River Laboratories International, Inc. and Madrigal Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CRL vs MDGL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Charles River Laboratories International, Inc. (CRL) | Madrigal Pharmaceuticals, Inc. (MDGL) | |
|---|---|---|
| Market cap | $11.1B | $11.0B |
| Revenue (latest FY) | $4.02B | $958.40M |
| Net income (latest FY) | $-144.34M | $-288.28M |
| Revenue growth (5y CAGR) | 6.5% | — |
| Net margin | -3.6% | -30.1% |
| Return on equity | -4.6% | -47.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 0 |
| Positive free cash flow | Yes | No |
See the full CRL vs MDGL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CRL's full financials → Open MDGL's full financials →More comparisons
Frequently asked questions
Which is bigger, CRL or MDGL?
Charles River Laboratories International, Inc. is larger by market capitalization — $11.1B versus $11.0B.
Which grows faster, CRL or MDGL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.